Medium Corp

SAN FRANCISCO, CA · CIK 0001894594 · Biotech

Custom affinity reagents (antibodies, aptamers, or binding proteins) designed and experimentally validated for specific research and diagnostic targets

medium.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$31M
1 Form D · Nov 2021
59 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$30,967,569
Form D · SECPress

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2082MYRACLE THERAPEUTICS INC——
2083Daedalus Systems Inc./de—$11M
2084Reclaim Pharmaceutical Waste Management, LLC——
2085Medium Corp—$31M
2086FORGE THERAPEUTICS INC——
2087CryptoMedix, Inc.—$100K
2088hC Bioscience—$12M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Press

1 article · matched on company name

Founders & Team

From Form D filings · 7 related persons
  • Teresa BurlisonExecutive Officer
  • Ben HorowitzDirector
  • Colin KaepernickDirector
  • Mariam NaficyDirector
  • Trevor O'BrienDirector · Executive Officer
  • Christopher StoneDirector
  • Evan WilliamsDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.